Flag of the European Union EU Clinical Trials Register Help

Clinical trials for II

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11,922 result(s) found for: II. Displaying page 1 of 597.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-003691-12 Sponsor Protocol Number: TUD-CIRC01-071 Start Date*: 2019-12-04
    Sponsor Name:Technische Universität Dresden
    Full Title: Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217
    Medical condition: Colon cancer stage II
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009954 Colon cancer stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005436-33 Sponsor Protocol Number: CITUR08-HM/SONOCOL Start Date*: 2009-01-21
    Sponsor Name:CHRU de TOURS
    Full Title: Apport de l’échographie doppler avec injection de contraste pour la prise en charge des cancers du col de l’utérus de stade IB et II traités par radiochimiothérapie concomitante
    Medical condition: Cancer du col de l'utérus épidermoïde ou adénocarcinome, de stade IB et IIA > à 4 cm ou IIB proximal
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008364 Cervix uteri cancer stage I LLT
    9.1 10008365 Cervix uteri cancer stage II LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002743-27 Sponsor Protocol Number: TKT024EXT Start Date*: 2004-12-23
    Sponsor Name:Shire Human Genetic Therapies INC.
    Full Title: An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
    Medical condition: Mucopolysaccharidosis Type II (MPS II or Hunter Syndrome)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10056889 PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-002316-23 Sponsor Protocol Number: CKJX839C12001B Start Date*: 2023-01-16
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who...
    Medical condition: Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10049593 Familial hypercholesterolaemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned) NO (Trial now transitioned) DE (Ongoing) NL (Trial now transitioned) HU (Trial now transitioned) GR (Trial now transitioned) FR (Trial now transitioned) SI (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004143-13 Sponsor Protocol Number: SHP-609-302 Start Date*: 2015-03-19
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase® in Patients with Hunter Syndrome...
    Medical condition: Hunter syndrome and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056889 Mucopolysaccharidosis II PT
    20.0 10010331 - Congenital, familial and genetic disorders 10056917 Hunter's syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014264-19 Sponsor Protocol Number: 0908038 Start Date*: 2010-01-14
    Sponsor Name:Clinique Mutualiste Chirurgicale
    Full Title: Prospective multicentric evaluation of a bladder preservation strategy using a combination of neoadjuvant chemotherapy with intensified MVAC (Méthotrexate + vinblastine + adriamicine + Cisplatine) ...
    Medical condition: bladder infiltrative urothelium carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10005021 Bladder carcinoma stage II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005754-23 Sponsor Protocol Number: ASSTBS-FRADIO-SPA-2020 Start Date*: 2021-04-06
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA Trial)
    Medical condition: prostate acinar adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007453 Carcinoma of the prostate metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001201 Adenocarcinoma of the prostate stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007456 Carcinoma of the prostate stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036951 Prostatic cancer stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036918 Prostate cancer stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001202 Adenocarcinoma of the prostate stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007457 Carcinoma of the prostate stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036952 Prostatic cancer stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036919 Prostate cancer stage III PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001023-21 Sponsor Protocol Number: DRL-17822/CD/004 Start Date*: 2011-06-30
    Sponsor Name:DR. REDDY'S LABORATORIES LIMITED
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients with Type II Hyperlipidemia
    Medical condition: Hyperlipidemia Type II
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10045254 Type II hyperlipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011079-57 Sponsor Protocol Number: BICG26UMCG-NIRF Start Date*: 2009-05-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Evaluation of Indocyanine Green (ICG) enhanced Near-InfraRed Fluorescence (NIRF) Imaging for Intra-Operative Sentinel Lymph Node (SLN) detection in Breast Surgery.
    Medical condition: Women above the age of 21 with core biopsy or cytology proven breast cancer stage I and II, eligible for lumpectomy and sentinel lymph node procedure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006194 Breast cancer NOS stage I LLT
    9.1 10006195 Breast cancer NOS stage II LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021600-24 Sponsor Protocol Number: FEC Start Date*: 2010-10-16
    Sponsor Name:IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
    Full Title: FEC neo-adjuvant chemotherapy followed by weekly Taxol administration combined with Trastuzumab in II-III stage HER2 positive breast cancer patients.Fase II trial.
    Medical condition: II/III stage HER2+ eligible for neoadjuvant chemotherapy breast cancer women
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007308 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003321-28 Sponsor Protocol Number: LTS13769 Start Date*: 2014-05-12
    Sponsor Name:Genzyme Corporation
    Full Title: An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of Avalglucosidase Alfa (NeoGAA, GZ402666) In Patients With Pom...
    Medical condition: Pompe disease (acid alpha-glucosidase deficiency)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036143 Pompe's disease LLT
    20.1 10010331 - Congenital, familial and genetic disorders 10053185 Glycogen storage disease type II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) DK (Completed) DE (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-000212-25 Sponsor Protocol Number: HGT-HIT-046 Start Date*: 2012-01-05
    Sponsor Name:Shire HGT Inc
    Full Title: An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction with Intravenous Elaprase® in Pediatric Pati...
    Medical condition: Treatment of Hunter syndrome and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056889 Mucopolysaccharidosis II PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-018188-29 Sponsor Protocol Number: Calendula study Start Date*: 2010-08-06
    Sponsor Name:Dept of Oncology
    Full Title: Randomised blinded trial of Calendula Officinalis compared with aqueos cream for the prevention of acute skin toxicity in relation to radiotherapy for breast cancer
    Medical condition: Patients operated for breast cancer who undergo postoperative adjuvant radiotherapy will be offered to participate in this randomized trial with the aim to reduce the risk of severe radiation skin ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006199 Breast cancer stage I LLT
    12.1 10006200 Breast cancer stage II LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002168-59 Sponsor Protocol Number: AGLU017-02 Start Date*: 2004-10-14
    Sponsor Name:GENZYME
    Full Title: An Open-Label, Multicenter, Multinational, Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid alpha- Glucosidase (rhGAA) Treatment in Patients > 6 and <...
    Medical condition: Treatment for Type II Glycogenosis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10053185 PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000582-37 Sponsor Protocol Number: CHOL00107 Start Date*: 2007-09-21
    Sponsor Name:Genzyme Europe BV
    Full Title: A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study of Colesevelam as Add-on Therapy in Patients with Familial Hypercholesterolaemia
    Medical condition: Familial hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049593 Familial hypercholesterolaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001811-59 Sponsor Protocol Number: D933RC00001 Start Date*: 2019-02-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Du...
    Medical condition: Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005010 Bladder cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005011 Bladder cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006808-11 Sponsor Protocol Number: Studio Zevalin Start Date*: 2006-08-11
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
    Full Title: Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin's lymphoma.
    Medical condition: Patients with untreated follicular non-Hodgkin's lymphoma grade 1 or 2 according to REAL classification.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061170 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003822-25 Sponsor Protocol Number: EORTC 08051 Start Date*: 2006-06-19
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Randomized Phase II Study Of Pemetrexed And Cisplatin As Either Induction or Adjuvant Chemotherapy In Stage IB-II Non-Small Cell Lung Cancer (NSCLC)
    Medical condition: Stage IB-II Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029518 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003595-38 Sponsor Protocol Number: AT845-01 Start Date*: 2020-11-20
    Sponsor Name:Audentes Therapeutics, Inc.
    Full Title: FORTIS: A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients with Late Onset Pompe Di...
    Medical condition: Late Onset Pompe Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10053185 Glycogen storage disease type II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-002848-41 Sponsor Protocol Number: CAPL180A2207 Start Date*: 2008-08-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled ascending dose study to evaluate the effect of APL180 on endothelial function in patients with familial hypercholesterolemia
    Medical condition: familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054380 Familial hypercholesterolemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 11:18:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA